Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases.

Saved in:
Bibliographic Details
Title: Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases.
Authors: Sun J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Wang C; Department of Epidemiology and Biostatistics, School of Public Health; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211116, China.; Department of Bioinformatics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211116, China., Zhang Y; Department of General Surgery, The First Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, 210029, China., Xu L; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Fang W; Cancer Biotherapy Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, China., Zhu Y; Department of Colorectal Surgery, The Zhejiang Cancer Hospital, Hangzhou, 310022, China., Zheng Y; Cancer Biotherapy Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310006, China., Chen X; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Xie X; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Hu X; Department of neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, 210029, China., Hu W; Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China., Zheng J; Department of Pathology, The Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, 210008, China., Li P; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Yu J; Department of Pathology and Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA., Mei Z; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.; Department of Oncology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, 211116, China., Cai X; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Wang B; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China., Hu Z; Department of Epidemiology and Biostatistics, School of Public Health; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211116, China., Shu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. shuyongqian@njmu.edu.cn., Shen H; Department of Epidemiology and Biostatistics, School of Public Health; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211116, China. hbshen@njmu.edu.cn., Gu Y; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. guyanhong@njmu.edu.cn.
Source: Nature communications [Nat Commun] 2019 Jul 18; Vol. 10 (1), pp. 3190. Date of Electronic Publication: 2019 Jul 18.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-1723
DOI:10.1038/s41467-019-10987-3